Apollo Hospitals HealthCo demerger: Q4 FY27 listing plan

What Apollo Hospitals has now confirmed

Apollo Hospitals Enterprise Limited (AHEL) has reiterated that the demerger of its HealthCo business remains on schedule. Management said shareholder approval is slated for June, with the process expected to conclude by Q4 FY27. The company expects the standalone entity to be listed around the January to March 2027 window. Apollo also linked this restructuring to a broader “value-unlocking roadmap” for the group’s pharmacy and digital health assets. The company’s guidance continues to anchor around a defined timeline and clear operational targets for the new entity. The update comes after regulatory steps already taken and additional approvals still pending. Management said it remains hopeful of completing the process by quarter four of FY27 as planned.

Structure of the proposed reorganisation

The planned structure is multi-layered and involves several entities under the Apollo group. Apollo HealthCo will be demerged from AHEL into a new entity, Apollo Healthtech Limited (AHTL). After that, the pharma distribution arm, Keimed, is expected to be merged into the new company. The new entity is intended to house Apollo’s omnichannel pharmacy and digital health operations in one listed vehicle. It will include the Apollo 24/7 digital platform, the offline pharmacy business under Apollo HealthCo, Keimed, and the telehealth services business. The company has positioned this as a consolidation of pharmacy distribution and digital health under one umbrella. The intended end-point of the restructuring is the listing of AHTL after the consolidation is completed.

Key dates: NCLT direction and the June 24 vote

Apollo has said the listing timeline is now solidified for Q4 FY27, following an NCLT order dated May 5, 2026. The NCLT has directed the company to hold a shareholders’ meeting. Apollo has scheduled the mandatory shareholder meeting for June 24, 2026 for final approval. Group CFO Krishnan Akhileswaran said that once shareholder approval comes through, the company expects the demerger plan to be in place by Q4 FY27. Management has also indicated that other clearances can take another six to eight months. The company has said it already has stock exchange approval. It is also expecting a no-objection certificate from the Securities and Exchange Board of India (SEBI).

Financial goals for HealthCo and the profitability path

Apollo has set a clear scale target for the demerged and consolidated business. Management has guided that Apollo HealthCo is expected to be around ₹20,000 crore on a consolidated basis in the current year. Next year, by Q4, the company expects to reach a revenue run rate of ₹25,000 crore. Alongside that, management has guided for an exit EBITDA margin of about 7%, with another commentary suggesting a 6% to 7% margin range. The ₹25,000 crore figure includes the merged distribution business. The company has framed this as a meaningful improvement in the earnings profile versus the earlier loss-making history cited for the digital and pharmacy business. These targets are central to how Apollo is positioning the listing to investors.

Apollo 24/7 and the cash breakeven milestone

The Apollo 24/7 digital platform is expected to reach cash breakeven by Q1 FY27. A top company executive told Business Standard that Apollo HealthCo is expected to achieve cash breakeven by the current quarter (Q1 FY27). This cash breakeven target is an operating milestone that sits ahead of the demerger completion timeline. It also matters because the demerged company will include Apollo 24/7 along with pharmacies and distribution. While the company has not provided quarterly cash burn numbers in this update, it has tied the restructuring to improving visibility on the unit economics. The breakeven guidance indicates the company wants the platform’s financial trajectory to be clearer before listing. The Q1 FY27 breakeven target and Q4 FY27 listing target together create a sequenced roadmap.

Portfolio moves: Cradle deal and deployment into diagnostics

Apollo Hospitals is also streamlining other parts of its portfolio as the listing plan progresses. The company said it is merging its Cradle business at a premium 35x EBITDA multiple. It also said it is raising ₹750 crore from its fertility business merger. Apollo has indicated that these funds are earmarked for aggressive expansion in diagnostics and primary care. The restructuring and the capital raise are being communicated as parallel steps to sharpen business focus. The company’s messaging links these moves to preparation for the HealthCo listing at a ₹25,000 crore annualised revenue scale. While valuation details beyond the multiple were not provided, the transaction is being framed as part of a broader reallocation of capital. The near-term use of funds is focused on diagnostics and primary care capacity build-out.

International patient mix: Bangladesh impact fades in Q3 FY26

Apollo Hospitals has also provided an operational update on international patient revenue trends. The company said it is already out of the impact from the Bangladesh crisis in overseas patient inflow due to diversification to new regions. International patient revenue rose 28% year-on-year during Q3 FY26, after two years of disruption tied to Bangladesh. In Q3 FY26, international patients constituted around 6% or ₹190 crore of total revenue of ₹3,183 crore. Apollo said patient mix shifted toward Africa, West Asia, and South East Asia, while Bangladesh dipped. According to company data, inflows from Bangladesh fell to 7% to 8% during Q3 FY26 from about 30% in early 2024. The company’s numbers highlight how geographic diversification has changed the international patient base. This operating context sits alongside the restructuring narrative, as Apollo continues to build multiple growth engines.

Shareholder economics and what investors were told

Investor-facing commentary has also outlined a share entitlement expectation post-demerger. As per management commentary captured in an investor discussion, for every 100 shares an investor holds in Apollo Hospitals, the investor would get 195 shares of the pharmacy and digital health business when it is demerged. The same commentary reiterated that the new company is expected to list around the January to March 2027 timeframe. Management also reiterated the revenue and margin ambition, stating the business should be around ₹25,000 crore in revenue by then with a 6% to 7% EBITDA margin. The company also described the value-unlocking rationale, especially since the digital health and pharmacy business has historically seen losses. The key message is that a separate listing could help investors assess the hospital business and the digital pharmacy business independently. The company has not provided a record date or a final ratio document in this update beyond the stated share expectation.

Approvals and milestones at a glance

Why this demerger matters for the market narrative

The demerger is significant because it separates Apollo’s asset-heavy hospital operations from the pharmacy, distribution, and digital health platform housed under HealthCo. Apollo has provided a specific timeline anchored by an NCLT-directed vote and a Q4 FY27 listing target, which reduces uncertainty compared with earlier “18 to 21 months” guidance. The financial targets also set a measurable bar: ₹25,000 crore revenue run rate and a 7% exit EBITDA margin for the consolidated entity. For Apollo, the plan also consolidates multiple consumer-facing and distribution businesses into one structure, including Keimed and Apollo 24/7. Separately, Apollo is highlighting cash breakeven expectations for its digital platform by Q1 FY27, suggesting a push to improve the operating profile before listing. Alongside these, portfolio actions such as the Cradle merger at 35x EBITDA and the ₹750 crore raised from the fertility business merger point to active capital recycling. The next key checkpoint is June 24, 2026, after which the process timeline will hinge on remaining regulatory clearances.

Conclusion

Apollo Hospitals has reaffirmed that the Apollo HealthCo demerger remains on track, with a shareholder vote scheduled for June 24, 2026 and a targeted listing by Q4 FY27. The new listed entity, Apollo Healthtech Limited, is expected to consolidate Apollo’s pharmacies, Keimed distribution, Apollo 24/7, and telehealth services. Management has paired the timeline with operating milestones, including a ₹25,000 crore revenue run rate goal and an exit EBITDA margin of about 7%, and cash breakeven for Apollo 24/7 by Q1 FY27. The next set of updates is likely to revolve around shareholder approval outcomes and the pace of remaining regulatory clearances, including SEBI’s no-objection.